CHMP backs once-weekly subcutaneous option for systemic lupus erythematosus
Category: News
Designation supports phase 3 launch in watch-and-wait patients in 2026
Applied Research Collaborations to drive innovation and tackle inequalities across England
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers
Three-year partnership to expand at-home health checks and vaccination access via NHS App
Linzagolix with add-back Therapy accepted for use within NHS Scotland
Blenrep combination offers improved survival for those ineligible for lenalidomide
Dutch biotech’s ORE-001 shows strong potential to prevent ileus after major surgery
